Clinical trial
Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL…
NCT00430443 · Callisto Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00430443 |
|---|---|
| Title | Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML |
| Official title | Phase I Study of Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed Acute Lymphocytic Leukemia and Acute Myelogeneous Leukemia |
| Lead sponsor | Callisto Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | Liposomal Annamycin |
| Enrollment | 3 |
| Start date | Feb 1, 2007 |
| Completion | Jan 1, 2009 |
| First posted | Feb 1, 2007 |
| Last update posted | Aug 31, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: